New Study Links Excess Screen Time To Heart Risks In Children: How To Protect Your Child
So, let's dive deep into the research, break down the heart health ripple effects for Indian families, and walk you through practical, culturally attuned strategies to reduce screen time and support healthy sleep and routines. Read on to know how small tweaks today can safeguard our children's hearts for decades to come.
Understanding The Study: What Was Discovered?
Researchers used two Danish longitudinal cohorts totalling over 1,000 mother child or adolescent pairs (COPSAC2010 and COPSAC2000). Screen time was parent reported or self reported; sleep and physical activity were objectively measured using accelerometers over a two week span. Cardiometabolic risk (CMR) was computed using five markers-waist circumference, systolic blood pressure, HDL (good) cholesterol, triglycerides, and blood glucose.
Key findings of the study:
Each extra hour of screen time raised cardiometabolic risk by around 0.08 standard deviations in children (6-10 years) and roughly 0.13 in adolescents (18 years).
Sleep played a crucial role because children with shorter or later sleep schedules showed significantly stronger risk ties.
Sleep duration mediated around 12% of the screen time cardiometabolic risk link, highlighting that better sleep can buffer some harm.
A distinct "screen time fingerprint" of 37 blood-based biomarkers (metabolomics signature) was identified, offering a biological signal connecting screen habits to metabolic changes.
Adolescents also showed higher predicted 10 year adult cardiovascular disease risk based on that signature.
The study is observational-not proving causality, but showing dose dependent associations and rich mechanistic insights.
Why This Study Matters For Indian Parents And Kids
Though the data are Danish, the findings resonate across geographies, including India. Screen time among Indian children has surged (especially thanks to the increase in online classes and smartphone usage since 2020), sleep is often compromised, and cardiometabolic issues like childhood obesity and insulin resistance are rising. Here are a few more links that can be clearly made between this study and global as well as Indian kids' habits.
Sedentary habits are heart harmful: This and previous studies have shown sedentary screen time contributes to increased heart weight and structural changes, even when body weight and blood pressure remain normal.
Sleep disruptions add to risk: Screens before bed, common in Indian households where family dinner time is also often spent in front of the television, delay sleep onset via blue light and overstimulation, worsening metabolic outcomes.
Language and development: Excessive screens, especially in early years, undermine face to face interaction and cognitive development and academic readiness, all aggravating the broader picture.
Practical, Friendly Tips To Reduce Screen Time And Boost Heart Health In Children
If you, as a parent or guardian, want to reduce your children's screen time and simultaneously boost heart health, then here are a few easy, practical and yet, friendly ways to do so:
Set daily screen time limits
Keep children's leisure screen time under two hours per day, excluding school-related use. This helps in lowering their cumulative exposure. Another friendly trick? Allow screen time for specific shows or cartoon slots in your chosen language, so it doesn't spill over into hours of aimless scrolling.
Create screen-free zones and times
Identify parts of the day or areas in your home where screens are not allowed-such as the dining table, during prayers, meditation or exercise hours, or before bedtime. Establishing a "no phone during chai time" or "family lunch = no devices" routine can work wonders.
Avoid screens at least one hour before bedtime
This allows melatonin (the sleep hormone) to function properly, promoting deeper sleep. Instead of TV or mobile devices, switch to story time in your child's mother tongue, light reading, or calming music-habits that also support emotional bonding.
Encourage outdoor or indoor active play
Physical activity helps burn off sedentary time and improves heart function. For younger kids, make time for games like skipping rope. If outdoor space is a problem, even dancing to your family's favourite tunes at home helps.
Be a role model and limit your own screen time
Children mimic what they see. If you're constantly on your phone, they'll assume it's normal. So, during family time, put your phone away. Instead, cook together, play a board game, or go for a short family walk. Lead by example.
Promote hands-on hobbies and quiet time
Offer your child alternatives to screen-based entertainment. Encourage art, building blocks, puzzles, colouring, local crafts, or DIY activities like drawing a comic strip or writing their own short story. This not only limits screen time but boosts creativity.
Use parental controls smartly
Many phones and tablets come with built-in parental controls. Set daily screen limits or schedule "downtime" on devices.
Prioritize good sleep hygiene
Since sleep plays a big role in offsetting the harms of screen time, ensure your child goes to bed and wakes up at regular times, even on weekends. Keep bedrooms screen-free and create a calming bedtime routine like a warm bath or simple prayers.
Communicate openly-not just rules, but reasons
Instead of commanding "no phone!", explain why. Use simple language: "Our hearts grow stronger when we play, move, sleep well, and don't stare at screens too much." The more kids understand the why, the more they'll cooperate with the how.
A Note on Holistic Heart Health
Beyond screens, combine healthy meals (local fruits, dals, millets), regular movement, and stress free routines like family walks or storytelling time. As highlighted before, earlier onset of metabolic disease calls for integrated approaches and screen limits are an entry point to broader heart healthy lifestyles.
This study offers an early warning, but also hope. By trimming screen time and nurturing sleep and active routines, parents can safeguard their kids' hearts both now and for the long haul.
Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
31 minutes ago
- Hans India
IIT Delhi's new method to cut textile waste, recycle discarded denims to good quality garments
New Delhi: A team of researchers from IIT Delhi has developed a new method to recycle denim waste to knitted garments without compromising quality. The findings will also help reduce textile waste -- the discarded textiles and clothing after their use -- which end up in landfills. India accumulates around 3.9 million tonnes of domestic post-consumer textile waste annually, of which only 4 per cent is recycled. Those recycled lose fibre strength and face variability in colour and quality. However, with the novel method, the IIT researchers found that up to 50 per cent of recycled yarns can be used in knitted clothing without deteriorating the feel of the product. 'To reduce the roughness of recycled yarns, a softening treatment was applied to the fabric, which ensured that the tactile feel of the final product is the same as that of virgin products, said Prof Abhijit Majumdar, Dept. of Textiles and Fibre Engineering, IIT Delhi. 'We have demonstrated our work with denim waste, and it can be extended with any other textile waste,' he added. In the study, detailed in the Journal of Cleaner Production, the team recycled waste denim into yarns, ensuring minimum damage to the fibre properties by optimising the process conditions. Recycled yarns were then blended into knitted fabric using the seamless whole garment technology. Knitted garments were produced, varying the recycled yarn content from 25 per cent to 75 per cent. Another key aspect of this research was to quantify the environmental benefits through life cycle assessment (LCA) in the Indian context. Analysis by the IIT Delhi team showed that around 30-40 per cent of environmental impacts can be mitigated in terms of greenhouse gas emission, acid rain, and fossil fuel depletion, whereas for ozone layer depletion, it is around 60 per cent. As the use of recycled fibres could reduce the use of virgin cotton, the pesticides, fertilisers and water used for cultivation can also be saved. Among the processes involved, the cotton cultivation stage itself contributes 24 per cent to global warming, making the virgin yarns less environment-friendly. 'The research team is now exploring the possibility of recycling textile waste materials multiple times,' added Prof B.S. Butola, Dept. of Textile and Fibre Engineering, IIT Delhi.
News18
an hour ago
- News18
Hyderabad Pharma Firm To Make Drug For Hard-To-Treat Bladder Cancer After Local Trials Waiver
For Indian patients battling aggressive bladder cancer driven by specific gene changes, a vital treatment may soon be available. Citing an 'unmet medical need" India's top drug advisory panel has approved a pharmaceutical firm's request to make and sell erdafitinib tablets in India by skipping a local third-phase trial but needing a post-launch fourth phase study. Hyderabad-based Natco Pharma has presented the proposal for the grant of permission to manufacture and market erdafitinib in three different strengths along with the 'justification" for a waiver on local third-phase clinical trials, as per the minutes of the meeting of the technical committee dated July 17. 'After detailed deliberation, the committee opined that there is an unmet medical need for the proposed indication in the country," said the minutes, which were accessed by News18. 'The committee recommended for the grant of permission to manufacture and market the drug Erdafitinib Tablet 3 mg, 4 mg and 5 mg with local Phase III clinical trial waiver." This marks a significant shift from the 2023 stance, when the subject expert committee (SEC), functioning under Central Drugs Standard Control Organisation (CDSCO), had rejected Natco's request for a Phase-III waiver. After reviewing the bioequivalence data, the SEC asked the company to 'submit the Phase-III clinical trial protocol before the committee for further consideration". That earlier decision underscored the caution about approving cancer treatments without robust local safety and efficacy data. According to the GLOBOCAN 2020 database, bladder cancer is the 17th most common malignancy in India. The five-year prevalence appears to be 3.57 per 1,00,000 population, leading to about 11,000 deaths each year. The incidence of bladder cancer is higher in males as compared to females. Data shows that bladder cancer incidence does vary across India. Among males, Delhi had the highest incidence rates followed by Thiruvananthapuram and Kolkata, and the lowest rate was in Dibrugarh. When it comes to females, the rate is highest in Delhi followed by Mumbai and Mizoram, respectively, and lowest in Barshi. Over time, bladder cancer incidence has increased in Delhi, Bengaluru and Mumbai, while it has decreased in Chennai. WHAT MAKES ERDAFITINIB IMPORTANT? Erdafitinib is a targeted therapy that inhibits the fibroblast growth factor receptor (FGFR) – a key driver of rapid tumour growth in certain bladder cancers. The FGFR gene gives the body instructions to make FGFR proteins, which sit on the surface of cells. These proteins receive growth signals (called fibroblast growth factors) and tell the cell when to grow, divide, or repair itself. On January 19, 2024, the US FDA approved erdafitinib, sold under the brand name Balversa, developed by Janssen Biotech, a Johnson & Johnson company. The drug has been approved for adults with advanced or metastatic bladder cancer that has certain FGFR3 gene changes, confirmed by an approved test. It can be used if the cancer has worsened after at least one previous systemic treatment. It is not meant for patients who could still benefit from PD-1 or PD-L1 immunotherapy and have not yet tried it. ONCOLOGISTS WELCOME THE MOVE According to the sellers on the online platform Indiamart, the bottle containing 56 tablets of 4mg Erdafitinib is sold at Rs 7,000, which is Rs 125 per tablet. With local manufacturing, however, the cost is expected to drop by more than 50 per cent. 'It's a good drug for bladder cancer patients with locally advanced disease not responding to chemotherapy. This is targeted therapy that blocks fibroblast growth factor receptor (FGFR). This fibroblast growth factor helps cancer grow fast. This medicine blocks this growth and helps control cancer," said Dr Satya Prakash Yadav, director of paediatric haematology-oncology and bone marrow transplant at Medanta Hospital. Similarly, Dr Pragya Shukla, who leads the clinical oncology department at Delhi State Cancer Institute, said the drug is for FGFR-altered metastatic urothelium, which has failed on multiple lines of chemotherapy and has shown benefits in overall survival in this particular group of patients. As the panel cited 'unmet demand", Dr Shukla said: 'The drug should definitely benefit a particular group of patients waiting for a targeted therapy." WHAT COMES NEXT? If the technical committee's recommendation is adopted into a final CDSCO order, Natco Pharma may roll out erdafitinib across India – provided it submits a robust Phase-IV study protocol within three months of approval. A fourth phase trial is the stage of research that happens after a drug has been approved by regulators and is already being sold in the market. It is also called post-marketing surveillance or post-approval study. It can reveal safety issues, interactions, or benefits that did not appear in smaller or shorter trials before, and at times lead to changes in how the drug is prescribed – or even withdrawal if serious risks are found.
Hindustan Times
2 hours ago
- Hindustan Times
Govt issues note on birth, death registration
Dr Babita Kamlapurkar, deputy director, health services issued a note on Monday on mandatory registration of births and deaths. For births or deaths at home, the head of the family is responsible for reporting them, officials said, adding that birth registration can be done without a name, which can be added later. (REPRESENTATIVE PHOTO) 'The first copy of a birth or death certificate is issued free of cost and additional copies can be obtained on payment. Corrections are allowed under certain conditions, and foreign births can be registered at Indian embassies abroad and later in India, though foreign deaths cannot be registered here,' she said. The Registration of Births and Deaths Act, 1969, implemented by the central government, governs the registration process. For births or deaths at home, the head of the family is responsible for reporting them, officials said, adding that birth registration can be done without a name, which can be added later. Delay in registration of birth and death by one year needs a magistrate's order and requisite fee.
